Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X:
“The VWF : GPIbM and VWF:RCo appear the most suitable assays for monitoring VWF activity in iTTP patients treatment with caplacizumab. The VWF:GPIbR have a limited ability to detect caplacizumab’s inhibition. The VWF:Ab assay is unsuitable for this purpose ”
Title: Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.
Authors: Paola Colpani, Luciano Baronciani, Ilaria Mancini, Cristina Novembrino, Anna Lecchi, Giovanna Cozzi, Pasqualina De Leo, Massimo Boscolo Anzoletti, Silvia La Marca, Marco Boscarino, Maria Teresa Pagliari, Andrea Artoni, Flora Peyvandi
Read the full article here.
Stay updated with Hemostasis Today.
-
Apr 27, 2026, 07:08Jeff Schaffnit: Global Voices in Hemophilia Care at the World Federation of Hemophilia World Congress
-
Apr 27, 2026, 06:44Andrew M. Evens: Award-Winning Research from the British Society for Haematology 66th Annual Meeting
-
Apr 27, 2026, 05:19Harshal Kale: Celebrating Hemophilia Partnerships on a Global Stage
-
Apr 26, 2026, 17:17Ajigbotosho Barakat: Leg Strength as a Key to Healthy Aging
-
Apr 26, 2026, 17:02Francisco Chacón-Lozsán: Limited Evidence Methylene Blue in Vasoplegic Shock
-
Apr 26, 2026, 16:57Gopal Patidar: Key Areas of Haemovigilance in ISBT Transfusion Today
-
Apr 26, 2026, 16:56Cathy Harrison: Oral Health in Older Adults Assessing the Impact of Ageing, Heart Failure, and Social Isolation
-
Apr 26, 2026, 15:08Andreas Ejlegård: Rebalancing Thrombosis and Hemostasis Through Mechanistic Innovation
-
Apr 26, 2026, 14:55Vanessa Simioni Faria: Precision Anticoagulation and Expanding Donor Frontiers